Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiquimod hydrogel - Surge Therapeutics

Next Previous
Drug Profile

Resiquimod hydrogel - Surge Therapeutics

Alternative Names: Resiquimod hydrogel; STM-416; STM-416p; STM0416 SURGERx

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Surge Therapeutics
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer
  • Phase I Prostate cancer

Most Recent Events

  • 08 May 2025 Phase-I clinical trials in Prostate cancer in USA (unspecified route) (NCT06450106)
  • 13 Jun 2024 SURGE Therapeutics plans a phase I trial for Prostate Cancer (Adjuvant therapy) in September 2024 (NCT06450106)
  • 18 Aug 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top